Jubilant Ingrevia - Improvement In Global Demand, Pricing Of Molecules Holds Key: Prabhudas Lilladher
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
Jubilant Ingrevia hosted an analyst meet ahead of its listing on exchanges, expected in March 2021. Management guided -
1. double digit growth in revenue over FY21-23E,
2. improvement in Ebitdam from current nine months FY21 17% to 20% plus in coming years,
3. net debt reduction and
4. Capex of Rs 5.5 billion/Rs 1 billion/Rs 2.5 billion for specialty/nutrition/life science ingredient segment in three years
Its future growth is dependent on revenue originating from three main sources -
- Specialty chemicals,
- Nutrition/health solutions and
- Life science chemicals.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.